CClinicalTrials.gg
CompletedNCT03433079Updated Feb 14, 2018

Acute Kidney Injury in Severe Trauma

An observational study in Acute Kidney Injury, sponsored by University Hospital Ostrava. Completed at 1 site in Czechia. Open to participants aged 18 Years to 99 Years. Per ClinicalTrials.gov, last updated 2018-02-14.

Sponsored by University Hospital Ostrava · Observational

Study type
Observational
Model
Case-only
Time perspective
Prospective
Enrollment
81
Ages
18 Years to 99 Years
Sex
All
01

Study summary

Acute kidney injury (AKI) represents a serious complication following severe injury associated with adverse outcome. Main goals of the presented study were to define the incidence of AKI and to evaluate the validity of AKI biomarker neutrophil gelatinase-associated lipocalin (NGAL) in AKI prediction in severely injured patients. Secondary goals were to determine the time-dependent role of injury-related tissue hypoxia, systemic inflammatory response, and rhabdomyolysis in the pathophysiology of AKI.

Read the detailed description

The main goal of the presented study was to define the epidemiology of AKI and to evaluate the validity of AKI biomarker neutrophil gelatinase-associated lipocalin in AKI prediction in severely injured patients with Injury Severity Score (ISS) > 24. Secondary goals were to determine the time-dependent role of insults associated directly with the intensity of injury (tissue hypoxia, systemic inflammatory response and/or infection, rhabdomyolysis) in the pathophysiology of AKI.

The study was performed in a single center at the University Hospital in Ostrava in the Czech Republic. The Ethics Committee of the University Hospital Ostrava approved the study, which conformed to the tenets of the Declaration of Helsinki. Each of the awake and conscious study subjects signed the Informed Consent Form approved by the Ethics Committee of the University Hospital Ostrava. For enrolment of unconscious study subjects who were unable to sign informed consent, approval of two independent (i.e. not involved in the study) physicians was needed.

Patients and methods: All adult severely injured patients defined by Injury Severity Scale (ISS) > 24 admitted to the Department of Anaesthesiology and Intensive Care in University Hospital Ostrava between June 2013 and December 2015 were enrolled into the study. Subjects were screened for AKI presence defined by Kidney Disease: Improving Global Outcomes (KDIGO) criteria daily up to 8 days after injury. Arterial levels of neutrophil gelatinase-associated lipocalin (NGAL), lactate, interleukin-6 (IL-6), procalcitonin (PCT) and myoglobin were investigated at the time points 24 hours (T1), 48 hours (T2) and 96 hours (T3) after injury.

Methods All consecutive severely injured patients (ISS > 24) older than 18 years of age were enrolled in this prospective observational study between June 2013 and December 2015. All participants were admitted to the Level 1 Trauma Centre (Department of Anaesthesiology and Critical Care) at the University Hospital of Ostrava. Exclusion criteria included age \< 18 years, history of kidney disease, pregnancy, death within 24 hours after injury, unsurvivable injury with an end of life decision (withhold or withdraw of therapy) pronounced within 24 hours after injury and, finally, clinical signs of brain death within 24 hours after injury.

Basic observed demographic parameters included age, ISS and mechanism of injury. The laboratory parameters included blood NGAL; arterial lactate level, IL-6, PCT and myoglobin at the 24 hours (T1), 48 hours (T2) and 96 hours (T3) after injury. Serum Creatinine level was assessed once daily at 6.00 a.m. and urine output collected hourly from admission (D0) to Day 8 were the basis for evaluation of AKI presence. Because of the recent pre-injury values of Creatinine were unknown almost in all of the subjects, first serum Creatinine level (sCr) taken on admission to the emergency room was used as a baseline reference value.

All diagnostic and therapeutic interventions were performed in accordance with guidelines and standards for the treatment of the critically injured patients. The study protocol does not contain any additional diagnostic or therapeutic intervention except the laboratory investigations mentioned above.

Early AKI defined according to KDIGO criteria occurs in one-third of victims of severe injury. Blood NGAL levels during the first 96 hours after injury are significantly higher in patients who subsequently develop AKI. Prolonged tissue hypoxia, excessive and prolonged activation of inflammatory response and rhabdomyolysis are factors contributing the development of AKI.

02

Conditions studied

  • Acute Kidney Injury

Keywords

  • Acute Kidney Injury
  • Severe Trauma
  • NGAL
  • Tissue Hypoxia
  • Inflammatory Response
  • Rhabdomyolysis
03

Who can participate

Ages eligible
18 Years to 99 Years
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Severely injured patients (ISS > 24) older than 18 years.

Inclusion criteria

  • severe injury (ISS >24)

Exclusion criteria

Exclusion Criteria:

  • age \< 18 years
  • history of kidney disease
  • pregnancy
  • death within 24 hours after injury
  • unsurvivable injury (withheld or withdrawn therapy) within 24 hours after injury
  • clinical signs of brain death within 24 hours after injury
04

Study design

Observational model
Case-only
Time perspective
Prospective
Enrollment
81 participants (actual)
Patient registry
No

Groups and cohorts

  • Acute Kidney Injury

    Patients \> 18 years of age with acute kidney injury were enroled into the study. Arterial levels of neutrophil gelatinase-associated lipocalin (NGAL), arterial lactate, interleukin-6 (IL-6), procalcitonin (PCT) and myoglobin were investigated in all patients.

    Diagnostic Test: Neutrophil gelatinase-associated lipocalin (NGAL) · Diagnostic Test: Arterial lactate · Diagnostic Test: Interleukin-6 (IL-6) · Diagnostic Test: Procalcitonin (PCT) · Diagnostic Test: Myoglobin

Interventions

  • Diagnostic testNeutrophil gelatinase-associated lipocalin (NGAL)

    Blood neutrophil gelatinase-associated lipocalin (NGAL) test was performed in all patients.

  • Diagnostic testArterial lactate

    Arterial lactate level was assessed in all patients.

  • Diagnostic testInterleukin-6 (IL-6)

    The level of interleukin-6 was assessed in all patients.

  • Diagnostic testProcalcitonin (PCT)

    The level of procalcitonin (PCT) was assessed in all patients.

  • Diagnostic testMyoglobin

    The level of myoglobin was assessed in all patients.

05

What researchers measure

Primary outcomes

  1. Acute Kidney Injury biomarker validity

    The main goal of the study was to evaluate the validity of AKI biomarker neutrophil gelatinase-associated lipocalin in AKI prediction in severely injured patients with Injury Severity Score (ISS) \> 24.

    Time frame: 36 months

Secondary outcomes

  1. Time-dependent role of insults

    Secondary outcome measure was to determine the time-dependend role of insults associated directly with intensity of injury (tissue hypoxia, systemic inflammatory response and/or infection, rhabdomyolysis) in the pathopfysiology of AKI.

    Time frame: 36 months

06

Study locations

1 site
  • University Hospital Ostrava
    Ostrava, Moravian-Silesian Region 70852, Czechia
07

Registry details

Key details

Study ID
NCT03433079
Lead sponsor
University Hospital Ostrava
Responsible party
Sponsor
First posted
Feb 14, 2018
Start date
Jun 1, 2013
Primary completion
Dec 31, 2015
Completion
Jan 31, 2016
Last update
Feb 14, 2018

Study contacts

Peter Sklienka, MD
principal investigator · University Hospital Ostrava

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion